A newly reported study by a Stanford Medicine-led team has provided what the researchers suggest is the strongest evidence yet that a vaccine can reduce the risk of dementia. Taking advantage of a particular public health policy in Wales that means eligibility for the shingles (herpes zoster) vaccine is based on an individual’s exact date of birth, the team analyzed the health records of older adults, discovering that those who received the live attenuated vaccine were 20% less likely to develop dementia over the next seven years than those who did not receive the vaccine.

The findings, published in Nature, support an emerging theory that viruses that affect the nervous system can increase the risk of dementia. In their paper (“A natural experiment on the effect of herpes zoster vaccination on dementia,”) research lead and senior author Pascal Geldsetzer, MD, PhD, assistant professor of medicine, and colleagues, concluded, “Our substantial effect sizes, combined with the relatively low cost of the zoster vaccine, imply that, if these findings are truly causal, the zoster vaccine will be both far more effective as well as cost-effective in preventing or delaying dementia than existing pharmaceutical interventions.”

Shingles, a viral infection that produces a painful rash, is caused by the same virus—varicella zoster virus (VZV)—that causes chicken pox. After people contract chicken pox, usually in childhood, the virus stays dormant in the nerve cells for life. In people who are older or have weakened immune systems, the dormant virus can reactivate and cause shingles.

Dementia affects more than 55 million people worldwide, with an estimated 10 million new cases every year. Decades of dementia research have largely focused on the accumulation of plaques and tangles in the brains of people with Alzheimer’s, the most common form of dementia. But a lack of breakthroughs in prevention or treatment is leading some researchers to explore other avenues, including the role of certain viral infections.

In their newly released Nature paper, Geldsetzer and colleagues pointed out, “Recently, evidence has grown that neurotropic herpesviruses may have a role in the pathogenesis of dementia. One approach to targeting herpesviruses is vaccination.” However the team continued, vaccines are increasingly being recognized as eliciting a broader immune response that can have important off-target effects. To date, they continued, “… studies in cohort and electronic health record data on the effect of vaccination receipt on dementia have simply compared the occurrence of dementia among those who received a given vaccination and those who did not.”

Such studies have to assume that characteristics that are different between vaccinated and unvaccinated individuals—and that are also related to dementia—have been sufficiently well measured and modeled so that there are no remaining factors that might confound any relationship between vaccination receipt and dementia. But, as the team commented, “This assumption of no confounding bias is often implausible because it has to be assumed that the study has detailed data on factors that are difficult to measure, such as personal motivation or health literacy.”

So, while previous studies based on health records have linked the shingles vaccine with lower dementia rates, they could not account for a major source of bias, in that people who are vaccinated also tend to be more health conscious in many difficult-to-measure ways. Behaviors such as diet and exercise, for example, are known to influence dementia rates, but are not included in health records.

“All these associational studies suffer from the basic problem that people who get vaccinated have different health behaviors than those who don’t,” said Geldsetzer. “In general, they’re seen as not being solid enough evidence to make any recommendations on.”

Two years ago Geldsetzer recognized a fortuitous “natural experiment” in the rollout of the shingles vaccine in Wales that offered a potential way to deal with this bias. “To provide causal as opposed to correlational evidence, we take advantage of the fact that, in Wales, eligibility for the zoster vaccine was determined on the basis of an individual’s exact date of birth,” the investigators explained. The vaccine being used at that time contained a live-attenuated, or weakened, form of the virus.

The vaccination program, which began Sept. 1, 2013, specified that anyone who was 79 on that date was eligible for the vaccine for one year. (People who were 78 would become eligible the next year for one year, and so on.) People who were 80 or older on Sept. 1, 2013, were out of luck—they would never become eligible for the vaccine. The authors summarized, “Those born before 2 September 1933 were ineligible and remained ineligible for life, whereas those born on or after 2 September 1933 were eligible for at least one year to receive the vaccine.”

These rules, designed to ration the limited supply of the vaccine, also meant that the slight difference in age between 79- and 80-year-olds made all the difference in who had access to the vaccine. By comparing people who turned 80 just before Sept. 1, 2013, with people who turned 80 just after, the researchers could isolate the effect of being eligible for the vaccine.

The circumstances, well-documented in the country’s health records, were about as close to a randomized controlled trial as you could get without conducting one, Geldsetzer pointed out. “Importantly, individuals who are only a few weeks apart in age are not expected to differ systematically from each other,” the authors commented. “That is, all potential confounding variables are in expectation balanced between our comparison groups.” By taking advantage of what they described as “this unique natural experiment” the scientists could avoid confounding “more credibly” than other studies that had compared vaccine recipients to non-recipients while trying to control for “the myriad of differences” between the groups.

For their reported study, Geldsetzer and colleagues looked at the health records of more than 280,000 older adults who were 71 to 88 years old and did not have dementia at the start of the vaccination program. They focused their analysis on those closest to either side of the eligibility threshold—comparing people who turned 80 in the week before the cutoff with those who turned 80 in the week after. “We know that if you take a thousand people at random born in one week and a thousand people at random born a week later, there shouldn’t be anything different about them on average,” Geldsetzer said. “They are similar to each other apart from this tiny difference in age.”

The same proportion of both groups likely would have wanted to get the vaccine, but only half, those almost 80, were allowed to by the eligibility rules. “What makes the study so powerful is that it’s essentially like a randomized trial with a control group—those a little bit too old to be eligible for the vaccine—and an intervention group—those just young enough to be eligible,” Geldsetzer added.

Over the next seven years, the researchers compared the health outcomes of people closest in age who were eligible and ineligible to receive the vaccine. By factoring in actual vaccination rates—about half of the population who were eligible received the vaccine, compared with almost none of the people who were ineligible—they could derive the effects of receiving the vaccine.

They found that, as expected, the vaccine reduced the occurrence over that seven-year period of shingles by about 37% for people who received the vaccine, similar to what had been found in clinical trials of the vaccine. (The live-attenuated vaccine’s effectiveness wanes over time.)

By 2020, one in eight older adults, who were by then 86 and 87 years of age, had been diagnosed with dementia. But those who received the shingles vaccine were 20% less likely to develop dementia than those who were unvaccinated. “Scaled to account for the fact that not all those who were eligible received the vaccine, we find that actually receiving the zoster vaccine reduced the probability of a new dementia diagnosis by 3.5 (95% CI = 0.6–7.1; P = 0.019) percentage points, corresponding to a relative reduction of 20.0%,” the team wrote. “It was a really striking finding,” Geldsetzer said. “This huge protective signal was there, any which way you looked at the data.”

The scientists searched high and low for other variables that might have influenced dementia risk but found the two groups to be indistinguishable in all characteristics. There was no difference in the level of education between the people who were eligible and ineligible, for example. Those who were eligible were not more likely to get other vaccinations or preventive treatments, nor were they less likely to be diagnosed with other common health conditions, such as diabetes, heart disease, and cancer. “… we have provided evidence from a series of analyses against any of the possible remaining sources of bias being a likely explanation of our findings,” the authors stated.

The only difference was the drop in dementia diagnoses. “Because of the unique way in which the vaccine was rolled out, bias in the analysis is much less likely than would usually be the case,” Geldsetzer said. The team further noted, “By taking advantage of the fact that the unique way in which the zoster vaccine was rolled out in Wales constitutes a natural experiment, and examining each possible remaining source of bias, our study provides evidence that is more likely to be causal in nature than the existing, exclusively associational, evidence on this topic.”

The team did still analyze the data in alternate ways—using different age ranges or looking only at deaths attributed to dementia, for example—but the link between vaccination and lower dementia rates remained. “The signal in our data was so strong, so clear and so persistent,” Geldsetzer said.

In a further finding, the study showed that protection against dementia was much more pronounced in women than in men. “We observed large differences in the effect of zoster vaccination on dementia between women and men, with women benefitting more than men,” the investigators wrote. This could be due to sex differences in immune response or in the way dementia develops, Geldsetzer suggested. Women on average have higher antibody responses to vaccination, for example, and shingles is more common in women than in men.

Whether the vaccine protects against dementia by revving up the immune system overall, by specifically reducing reactivations of the virus or by some other mechanism is still unknown. Also unknown is whether a newer version of the vaccine, which contains only certain proteins from the virus and is more effective at preventing shingles, may have a similar or even greater impact on dementia. “… because the newer recombinant subunit zoster vaccine (Shingrix) replaced the live-attenuated zoster vaccine (Zostavax) in the United Kingdom only in September 2023, which is after our follow-up period ended, our effect estimates apply to the live-attenuated zoster vaccine only,” the authors stated.

Geldsetzer hopes the new findings will inspire more funding for this line of research. “Other than investing into randomized trials, investments into basic science research on the potential role of VZV and the immune response to the zoster vaccine in the pathogenesis of dementia could provide critical mechanistic insights,” the authors further noted. “At least investing a subset of our resources into investigating these pathways could lead to breakthroughs in terms of treatment and prevention,” Geldsetzer added.

In the past two years, his team has replicated the Wales findings in health records from other countries, including England, Australia, New Zealand, and Canada, that had similar rollouts of the vaccine. “We just keep seeing this strong protective signal for dementia in dataset after dataset,” he said. Geldsetzer has set his sights on a large, randomized controlled trial, which would provide the strongest proof of cause and effect. Participants would be randomly assigned to receive the live-attenuated vaccine or a placebo shot. “It would be a very simple, pragmatic trial because we have a one-off intervention that we know is safe,” he noted.

Geldsetzer is seeking philanthropic funding for the trial as the live-attenuated vaccine is no longer manufactured by pharmaceutical companies. And such a trial might not take long to see results. A graph of the Wales data tracking the dementia rates of those who were eligible and ineligible for the vaccine shows the two curves began to separate in about a year and a half.

In a related News & Views, Anupam B. Jena, MD, PhD, at the Department of Health Care Policy at Harvard Medical School and the Department of Medicine, Massachusetts General Hospital, commented that while it’s not yet clear exactly how herpes zoster vaccination lowers the risk of dementia, the reported study has profound implications. “The vaccine could represent a cost-effective intervention that has public-health benefits strongly exceeding its intended purpose,” Jena stated. “Given the substantial economic and social burden of dementia, policymakers and healthcare providers might need to reassess the value of widespread herpes zoster vaccination, particularly in older adults.”

RNA editing therapy developer AIRNA has closed on an oversubscribed $155 million Series B financing it said will help it advance its lead program targeting Alpha-1 antitrypsin deficiency (AATD) into a Phase I/II trial this year.

The financing comes less than a year after AIRNA completed a $90 million Series A, of which $60 million was raised just last summer, and at a time when many other startups have struggled to raise venture capital. While president and CEO Kris Elverum said he can’t speak to the broader challenges of early-stage companies pursuing capital, he told GEN Edge that AIRNA’s success with investors reflected their alignment with the company’s three-prong approach to RNA drug development.

“The first is that RNA editing is clearly going to be a breakthrough modality that will deliver multiple medicines to help patients,” Elverum said. “We’re using multiple proven components from other [RNA] modalities—in particular siRNA—to enable optimal potency at lower doses with safe, infrequent, subcutaneous administration.”

The second, he continued, is AIRNA’s effort to develop a best-in-class AATD treatment that will deliver optimal potency at lower doses with safe, infrequent, subcutaneous administration. The third, Elverum added, is AIRNA’s commitment to building a top-tier pipeline.

“AIRNA stands alone in pursuing the introduction of healthy variants to address common diseases with RNA editing. And we’re really excited about the future for what we were going to be able to do across multiple different diseases to help people,” Elverum said.

AIR-001 is designed to restore functional alpha-1 antitrypsin (M-AAT) protein production by precisely repairing the SERPINA1 mutation (PiZ) to address the underlying cause of both lung and liver disease. According to AIRNA, AIR-001 offers potent and durable M-AAT production, convenient, subcutaneous dosing, and well-tolerated safety.

Growing field targets AATD

By focusing on AATD, AIRNA joins a growing field of drug developers targeting the genetic condition. Furthest along is Wave Life Sciences, whose AATD candidate WVE-006 succeeded last October in the first-ever clinical demonstration of RNA editing in humans by achieving positive proof-of-mechanism in an early-phase clinical trial.

Later this year, Wave expects to present additional data from its Phase Ib/IIa RestorAATion-2 trial (NCT06405633) assessing the effect of multiple doses and a higher dose level of WVE-006, on the production of healthy, wild-type, M-AAT protein, and potentially the effect of extended dose intervals. In March, Wave said multi-dosing of patients was ongoing in the trial’s 200 mg cohort, while a second single dose cohort of 400 mg has been launched.

Also pursuing an AATD therapy is Beam Therapeutics, which won FDA clearance for its investigational new drug (IND) application to expand into the United States its ongoing Phase I/II trial (NCT06389877) of BEAM-302, an in vivo liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents. BEAM-302 is designed to treat AATD by correcting the disease-causing PiZ mutation.

Earlier in March, Beam announced positive initial safety and efficacy data from the trial: a single infusion of BEAM-302 led to rapid, durable, and dose-dependent increases in total AAT across all three dosages studied (20 mg, 40 mg, and 60 mg), as well as new production of corrected protein (M-AAT) and decreases in mutant AAT (Z-AAT). At the high 60 mg dosage, total AAT at day 28 nearly tripled from 4.4 to 12.4 µM, above the 11 µM protective threshold. Beam said the data established clinical proof-of-concept for BEAM-302 as a potential treatment for AATD, as well as for in vivo base editing.

On March 18, Prime Medicine unveiled a preclinical prime editing program designed to treat AATD by using a universal liver lipid nanoparticle (LNP) to edit the PiZ mutation (also known as Pi*Z or E342K) in SERPINA1. Prime said LNP delivery of its Prime Editors showed up to 72% precise correction of the SERPINA1 gene in the hepatocytes of fully humanized mice, restoring over 95% of serum AAT to the corrected isoform, with healthy M-AAT protein in the serum at levels “well above” 20 µM.

A developer of CRISPR-based gene editing therapies, Intellia Therapeutics, ended development in January of its AATD candidate NTLA-3001 as part of a cost-cutting restructuring that included the planned elimination of 27% of its workforce during 2025. That would translate to approximately 110 jobs, based on the workforce total of 403 full-time employees as of February 14 disclosed by Intellia in its Form 10-K annual report.

Functional cure

“I think it’s more important to be best for patients than it is to be first in patients, and the unique opportunity that we have for patients with AATD is to bring them a functional cure that is a very potent repair of the mutation that’s causing their disease,” Elverum said.

“That repair allows for high levels of M-AAT protein to be produced, which is what’s really important for lung function, but to do so at low doses that can be safe and infrequently administered subcutaneously and allow patients to maintain control and freedom over their healthcare choices over the long term,” he added.

AIRNA’s AIR-001 leads a pipeline about which the company has not disclosed many details. Elverum said AIRNA’s therapeutic areas of interest include cardiometabolic disease, where its sole disclosed program entails introducing an as-yet undisclosed beneficial variant in vivo. It’s a similar mechanism to a program in AIRNA’s revealed pipeline for an undisclosed therapeutic area.

Elverum won’t say whether AIRNA’s focus on cardiometabolic disorders will include developing alternatives to glucagon-like peptide 1 (GLP-1) therapies. GLP-1s indicated for obesity and diabetes have grown into blockbuster drugs generating billions of dollars in sales for leading companies Novo Nordisk and Eli Lilly—but which have been linked in studies to side effects ranging from sagging facial skin (“Ozempic face”) to loss of muscle mass.

AIRNA develops therapies based on its RESTORE+™ RNA editing platform. RESTORE+ first targets a defined site in the RNA strand, activating changes to composition and functionality of a therapeutically relevant protein. The platform optimizes the chemistry, sequence, and delivery of oligos that precisely engage the RNA at the target site upon delivery into the cell, with the goal of enabling precise, efficient, and safe RNA editing.

Following target engagement, the oligo recruits endogenous adenosine deaminases acting on RNA (ADAR) to make an adenosine-to-inosine (A-to-I) edit at the target site that is read as guanosine (G). The A-to-I edit changes the code in the RNA, enabling the repair of pathogenic point mutations, or inducing therapeutically effective gain or loss-of-function mutations that precisely change protein activity.

Growth plan

With operations divided between its home base in Cambridge, MA, and Tübingen, Germany, where the company oversees a research hub, AIRNA foresees growth to its staff of over 50 people this year.

“Our growth is really going to be focused on that next stage of our development as we are bringing our medicines to patients. You can think about the medical function, the manufacturing function, and the like. That is going to be key for us as we move forward,” Elverum said.

The Series B round brings AIRNA to $245 million in total capital raised, and comes less than a year after AIRNA closed on $60 million in financing that was also oversubscribed—and brought the value of the company’s Series A to $90 million. AIRNA emerged from stealth in September 2023 with its first $30 million in initial financing from an investor syndicate led by ARCH Venture Partners.

Venrock Healthcare Capital Partners led the Series B financing, with Forbion Growth serving as co-leader. Participants in the Series B included RTW Investments, Nextech Invest, ARCH Venture Partners, Forbion Ventures, ND Capital, and other undisclosed new and existing investors.

In connection with the latest financing, Melissa McCracken, PhD, a partner at Nextech Invest, has been appointed to AIRNA’s board.

“AIRNA’s innovative approach to RNA editing has the distinctive potential to improve health across large populations by introducing healthy genetic variants for many conditions,” stated Dirk Kersten, managing partner at Forbion. “We are excited to support the expansion of AIRNA’s pipeline of life-changing medicines and the advancement AIR-001 into the clinic.”

An edible biofilm, obtained from agricultural and fishing waste and developed by researchers at the São Carlos Institute of Chemistry of the University of São Paulo (IQSC-USP) in Brazil, allows the shelf life of strawberries (Fragaria x ananassa Duch.) to be extended.

In laboratory tests, the researchers found that over 12 days of refrigerated storage, the fruit coated with the film lost 11% weight and took between 6 and 8 days to start becoming contaminated with fungi, compared to 4 days for fruit not covered with the material.

The results of the work, carried out in collaboration with researchers from EMBRAPA Instrumentation and the Federal University of São Carlos (UFSCar), are published in the journal Food Chemistry.

“By applying the coating, it was possible to double the shelf life of strawberries kept under refrigeration and delay the dehydration of the fruit, while preserving the taste, texture and volatile compounds that give the fruit its characteristic aroma,” Mirella Romanelli Vicente Bertolo, first author of the study and a postdoctoral researcher at EMBRAPA Instrumentation, says.

The work began during Bertolo’s doctoral studies at IQSC-USP under the supervision of Professor Stanislau Bogusz Junior. During their research, they developed a technique that allowed them to extract 84.2% more antioxidants—substances with preservative properties—from the peel of pomegranate (Punica granatum L.) using natural deep eutectic solvents (NADES).

“More than 40% of the pomegranate, depending on the variety, is made up of peel, which is wasted. Our idea was to use this waste to obtain extracts rich in phenolic compounds with antioxidant and antimicrobial activities,” says Bogusz.

With the success of developing the extraction method, the researchers decided to test the hypothesis of incorporating the antioxidants in pomegranate into coatings based on gelatin and chitosan—a polymer (natural polysaccharide) found in the skeletons of crustaceans such as shrimp—to develop a protective film for fruit.

“We chose to use chitosan extracted from squid glia [inner shells] through a process of deacetylation of the chitin found in this mollusk, because it doesn’t have the problem of allergenicity like that obtained from shrimp. And we combined this material with another polymer, in this case gelatin, to improve its mechanical properties,” explains Bogusz.

Highly perishable fruit

The strawberry was chosen as a model system to test the effectiveness of the biofilm because it is one of the items with the highest loss rates in Brazilian supermarkets due to its perishability and short shelf life of about less than seven days under refrigeration.

“The strawberry is a fruit that has very high respiratory activity and a very low pH [acidity]. It’s therefore very susceptible to microbial attack. It’s also very moist and the fruit is small. Based on this, we hypothesized that if the material we developed worked, it’d be effective on any other fruit,” says Bogusz.

To test this hypothesis, the researchers coated strawberries with the edible film by immersion and evaluated the effects of the material on the physicochemical, microbiological and volatile profile and sensory characteristics of the fruit over 12 days of refrigerated storage.

The results indicate that the material forms a film on the surface of the fruit that acts as a barrier to the passage of microorganisms, moisture loss and gas exchange, modifying the strawberry’s respiration. In this way, the coating slows down the metabolism of the fruit during the post-harvest period, thereby increasing its shelf life and preserving the color, firmness and bioactive compounds of the fruit.

“We found that the film made it possible to maintain the texture, delay contamination by microorganisms and reduce the loss of fruit mass, which is observed when the strawberry shrivels. This happens very often with uncoated fruit because it easily loses water and dehydrates,” says Bertolo.

According to the researcher, the film also made it possible to reduce the severity of fungal damage and improve the volatile profile of the fruit. “The material made it possible to preserve 40% more of the compounds responsible for the fruit’s aroma,” says Bertolo.

The biofilm also didn’t interfere with the sensory characteristics of the fruit, such as flavor, as confirmed by sensory analysis tests conducted with undergraduate chemistry students at IQSC-USP.

“The results of the tests showed that there were no differences in the taste, aroma or visual characteristics of strawberries coated with the material compared to strawberries without the film,” says Bertolo.

The researchers have filed a patent application for the formulation and intend to license the technology to interested companies.

Economic analyses indicate that the coating could cost an estimated BRL 0.15 per fruit.

“This is a cost that consumers may be willing to pay for fruit with a longer shelf life and greater usage,” Bertolo estimates.

Under the right conditions, duckweed essentially farms itself. Wastewater, ponds, puddles, swamps—you name it. If there’s enough sunlight and carbon dioxide, the aquatic plant can grow freely. But that’s not all that makes it intriguing. Packed inside duckweed’s tiny fronds is enormous potential as a soil enricher, a fuel source, protein-rich foods, and more. New findings at Cold Spring Harbor Laboratory (CSHL) could help bring all that potential to life. The research is published in the journal Current Biology.

CSHL Professor and HHMI Investigator Rob Martienssen and Computational Analyst Evan Ernst started working with duckweed over 15 years ago. They see their latest research as one of the most important and eye-opening studies on the plant to date. The team has developed new genome sequences for five duckweed species. The sequences reveal several genes that—when present or absent—may be behind the plant’s unique traits and versatility.

Martienssen explains, “The use of cutting-edge technology allowed us to make a catalog of genes that was extremely accurate. We could tell exactly which genes were there and which were not. A lot of genes that are missing are responsible for features of the plant—open stomata or the lack of roots. We could identify genes that were responsible for each trait.”

Stomata are pores on the surface of plants. They’re crucial for taking in carbon dioxide and releasing oxygen. Open stomata allow for greater intake, making them valuable for carbon capture technology. A lack of roots in some species further increases duckweed’s potential, making it easier for the plant to thrive in any watery environment.

Other species possess traits that showcase duckweed’s potential as a food and fuel source. Some traits promote high protein production, allowing for use as animal feed. Others promote starch accumulation, making the plant ripe for biofuel production. Several industries have taken notice. For now, they’re mostly concerned with the duckweed growing in their backyards.

Ernst explains, “Duckweed agriculture is in a nascent stage. Commercial growers are working with different species in the field, evaluating them in their own local situation. There’s so much variation within one species of duckweed—as much as you can find across all the species. So, having multiple genomes for multiple species is critical.”

Martienssen and Ernst hope their genomes will open the door to a new world of commercial applications. That said, their research may tell us as much about the plant’s past. Their study hints at how duckweed split off into different species 59 million years ago. Earth’s climate was quite extreme back then, so duckweed’s genes just might say something about the planet’s future, too.

Researchers at the Hong Kong University of Science and Technology (HKUST) have developed a cutting-edge AI-assisted 3D food printing solution that combines printing with infrared cooking, paving the way for safer, more efficient, and visually appealing food production. The study, “Advanced 3D Food Printing with Simultaneous Cooking and Generative AI Design,” was recently published in the journal Advanced Materials.

Traditional 3D food printing methods often require additional postprocessing steps, which can have unappealing food ingredients, imperfect shapes, and even potential microbial contamination.

To address these challenges, the team from the Division of Integrative Systems and Design (ISD) at HKUST has developed an AI-enhanced system that combines extrusion-based printing with simultaneous infrared heating for on-the-fly cooking of intricate starch-based foods. Using graphene heaters for cooking, they precisely controlled the cooking process, ensuring that starch-based food items retain their intended shape and quality.

The system is supported by AI-assisted design, which employs generative algorithms and Python scripts to craft intricate food patterns. By leveraging AI, the design process became accessible to even computer novices.

The research tackles issues such as shape retention and contamination risks and opens up exciting prospects for tailored nutrition—benefiting individuals with special dietary needs, including patients with dysphagia. From enhancing meal customization in elderly care centers and central kitchens to meeting special dietary needs and enabling creative culinary experiences in restaurants, the technology offers a versatile solution for various sectors.

“With its potential to streamline food production processes, improve food quality, and cater to individual preferences, this innovation can transform how food is prepared and served in diverse settings, paving the way for a future where personalized and visually appealing food creations are more accessible than ever before,” said Prof. Mitch Li Guijun, Assistant Professor of ISD, who led the research team.

“We’re excited about the potential of this technology to deliver customized, safe, and delicious food with a process that is both efficient and accessible. It represents a significant step forward in how we think about food creation,” Prof. Li added.

Connie Lee Kong-Wai, the paper’s first author and a Ph.D. student at HKUST, said, “We’ve reimagined what 3D food printing can achieve by merging technology and culinary creativity. Our cutting-edge integrative 3D food printing technology can potentially revolutionize personalized food creation.”

The research represents a collaborative effort spanning user-centric design, mechanical engineering, food science, chemistry, and AI. This cross-disciplinary approach brought together diverse expertise to tackle the complex challenges associated with 3D food printing.

Looking ahead, the team plans to refine the technology by examining the preservation of heat-sensitive vitamins and optimizing starch digestibility. Future studies will also focus on consumer acceptance through sensory evaluations involving target users such as children or hospital caretakers, ensuring that the system is ready for real-world applications.

Living cells are bustling with molecular machines that constantly process energy, matter, and information. Among these machines, proteins stand out, with enzymes being the most notable. These catalytic entities dramatically accelerate essential metabolic reactions by many orders of magnitude, facilitating the very processes that sustain life. While it has long been acknowledged that enzymes undergo movements during their catalytic cycles, measuring and predicting these internal motions and forces has proven extremely challenging.

A new study published in the journal Nature Physics addresses that challenge. It is the result of an international collaboration, led by Professor Tsvi Tlusty from the Department of Physics at UNIST and Professor Elisha Moses from the Physics Department at the Weizmann Institute of Science, Israel.

The collaboration integrated artificial intelligence (AI) models with molecular dynamics simulations to predict the internal dynamics of enzymes, alongside an innovative “nano-rheology” technique to measure these dynamics with unprecedented accuracy.

The computational and experimental results culminated in the development of a new viscoelastic model of enzymes, elucidating the intertwined effects of elastic forces arising from stretching or twisting molecular bonds and friction forces (viscosity) associated with bond breaking and reforming.

“Finally, this novel physical model can explain how subtle, nanoscale motions and forces within enzymes impact their biological functions. It allows us to perceive proteins as soft robots or programmable active matter,” said Professor Tlusty.

For years, scientists believed that our first memories vanished because the brain wasn’t developed enough to store them. But groundbreaking Yale research suggests otherwise.

Infants can encode and recall memories—even if we can’t access them later in life. By using brain scans and eye-tracking, researchers found that when an infant’s hippocampus is more active, they are more likely to remember an image. This discovery challenges the idea of “infantile amnesia” and raises a fascinating question: Could our earliest experiences still be hidden deep in our minds, just beyond reach?

Memories from Infancy: A Surprising Discovery

We learn an incredible amount in our earliest years, yet as adults, we struggle to recall specific events from that time. Scientists have long believed this is because the hippocampus, the part of the brain responsible for memory, is still developing throughout childhood and isn’t capable of storing memories in infancy. However, new research from Yale challenges this idea.

In a recent study, researchers presented infants with new images and later tested their recognition. They found that when an infant’s hippocampus was more active upon first seeing an image, the child was more likely to recognize it later.

Published on March 20 in Science, these findings suggest that memories can indeed be encoded in the brain during infancy. The next step for researchers is to explore what happens to these early memories over time.

Infantile Amnesia: The Mystery of Forgotten Early Memories

The inability to recall specific experiences from the first years of life is known as “infantile amnesia,” but studying it presents unique challenges.

“The hallmark of these types of memories, which we call episodic memories, is that you can describe them to others, but that’s off the table when you’re dealing with pre-verbal infants,” said Nick Turk-Browne, professor of psychology in Yale’s Faculty of Arts and Sciences, director of Yale’s Wu Tsai Institute, and senior author of the study.

How Scientists Measure Memory in Babies

For the study, the researchers wanted to identify a robust way to test infants’ episodic memories. The team, led by Tristan Yates, a graduate student at the time and now a postdoctoral researcher at Columbia University, used an approach in which they showed infants aged four months to two years an image of a new face, object, or scene. Later, after the infants had seen several other images, the researchers showed them a previously seen image next to a new one.

“When babies have seen something just once before, we expect them to look at it more when they see it again,” said Turk-Browne. “So in this task, if an infant stares at the previously seen image more than the new one next to it, that can be interpreted as the baby recognizing it as familiar.”

Hippocampal Activity: A Key to Infant Memory

In the new study, the research team, which over the past decade has pioneered methods for conducting functional magnetic resonance imaging (fMRI) with awake infants (which has historically been difficult because of infants’ short attention spans and inability to stay still or follow directions), measured activity in the infants’ hippocampus while they viewed the images.

Specifically, the researchers assessed whether hippocampal activity was related to the strength of an infant’s memories. They found that the greater the activity in the hippocampus when an infant was looking at a new image, the longer the infant looked at it when it reappeared later. And the posterior part of the hippocampus (the portion closer to the back of the head) where encoding activity was strongest is the same area that’s most associated with episodic memory in adults.

These findings were true across the whole sample of 26 infants, but they were strongest among those older than 12 months (half of the sample group). This age effect is leading to a more complete theory of how the hippocampus develops to support learning and memory, said Turk-Browne.

Different Memory Pathways: Statistical Learning vs. Episodic Memory

Previously, the research team found that the hippocampus of infants as young as three months old displayed a different type of memory called “statistical learning.” While episodic memory deals with specific events, like, say, sharing a Thai meal with out-of-town visitors last night, statistical learning is about extracting patterns across events, such as what restaurants look like, in which neighborhoods certain cuisines are found, or the typical cadence of being seated and served.

These two types of memories use different neuronal pathways in the hippocampus. And in past animal studies, researchers have shown that the statistical learning pathway, which is found in the more anterior part of the hippocampus (the area closer to the front of the head), develops earlier than that of episodic memory. Therefore, Turk-Browne suspected that episodic memory may appear later in infancy, around one year or older. He argues that this developmental progression makes sense when thinking about the needs of infants.

“Statistical learning is about extracting the structure in the world around us,” he said. “This is critical for the development of language, vision, concepts, and more. So it’s understandable why statistical learning may come into play earlier than episodic memory.”

What Happens to Early Memories?

Even still, the research team’s latest study shows that episodic memories can be encoded by the hippocampus earlier than previously thought, long before the earliest memories we can report as adults. So, what happens to these memories?

There are a few possibilities, says Turk-Browne. One is that the memories may not be converted into long-term storage and thus simply don’t last long. Another is that the memories are still there long after encoding and we just can’t access them. And Turk-Browne suspects it may be the latter.

In ongoing work, Turk-Browne’s team is testing whether infants, toddlers, and children can remember home videos taken from their perspective as (younger) babies, with tentative pilot results showing that these memories might persist until preschool age before fading.

Could Early Memories Be Retrieved?

The new findings, led by Yates, provides an important connection.

“Tristan’s work in humans is remarkably compatible with recent animal evidence that infantile amnesia is a retrieval problem,” said Turk-Browne. “We’re working to track the durability of hippocampal memories across childhood and even beginning to entertain the radical, almost sci-fi possibility that they may endure in some form into adulthood, despite being inaccessible.”

FORT BEND COUNTY, Texas — Fort Bend County Health and Human Services on Sunday announced that it has confirmed its first case of the measles in 2025.

The county said the case is in a woman between the ages of 50 and 60. They said the case is associated with international travel and is not connected to the West Texas outbreak.

“Your safety and well-being remain my top priority,” said Fort Bend County Judge KP George. “I urge all residents to check their immunization records, get vaccinated if necessary and stay vigilant for symptoms. Together, we can protect our families, neighbors and the greater Fort Bend community.”

Researchers from São Paulo State University (UNESP), at its Tupã campus in Brazil, have developed and tested a new geospatial intelligence methodology that can contribute more quickly and accurately to land use management and territorial planning projects.

With this tool, it was possible to precisely delineate areas of the Amazon rainforest, Cerrado vegetation (the Brazilian savannah-like biome), pastures and agricultural crops in a double-cropping system, something that can provide support for public policies aimed at agricultural production and environmental conservation.

The research is published in the journal AgriEngineering.

By combining data cube architecture (ready for analysis), disseminated in Brazil through the Brazil Data Cube project, led by the National Institute for Space Research (INPE), and the Geobia (Geographic Object-Based Image Analysis) approach, the scientists were able to identify vegetation and double cropping—for example, soy and corn—over the course of a harvest in the state of Mato Grosso. They used a time series of satellite images from NASA’s Modis (Moderate Resolution Imaging Spectroradiometer) sensor.

The results showed that the proposed combination, coupled with machine learning (artificial intelligence) algorithms, achieved 95% mapping accuracy.

Geobiology is a technique that allows satellite images to be processed using segmentations that group similar pixels into geo-objects and study their characteristics, such as shape, texture, and reflectance. In many cases, this allows for a more realistic interpretation. Data cubes, on the other hand, store information in dimensions—time and place—making it easier to aggregate and visualize information related to a specific location in a specific time period, such as crop areas in a harvest year.

Currently, mapping uses pixel image analysis in isolation, which ends up creating edge problems with blurring in some areas.

“Scientific work has highlighted spectral confusion in border zones between different land uses as an area for improvement. So we decided to segment the images and evaluate the geographic object as the minimum unit of analysis, rather than the pixel. It’s as if the image were broken down and classified according to each piece,” Michel Eustáquio Dantas Chaves, professor at the Faculty of Science and Engineering of UNESP and corresponding author of the article, told Agência FAPESP.

“In this way, we were able to reduce recurring edge errors and accurately identify the targets, even with moderate spatial resolution.”

Chaves has been using data cube architecture for several years to develop tools that contribute to analyses focused on the advancement of the agricultural frontier, especially in the Cerrado.

According to the professor, the methodology can be replicated to evaluate images from other Earth observation satellites, such as Landsat and Sentinel, which provide data for scientific studies, mapping and monitoring. Images from both are now being processed by the team coordinated by the professor.

Application in practice

Mato Grosso leads national grain production with 31.4% of the country’s total, followed by the states of Paraná (12.8%) and Rio Grande do Sul (11.8%). The state is expected to reach 97.3 million tons in the 2024/2025 harvest, an increase of 4.4% over the previous harvest, according to the National Supply Company (CONAB). Almost half of this production (46.1 million tons) is expected to be soybeans.

In addition, Mato Grosso is one of the most biodiverse states in the country, containing parts of three of Brazil’s six biomes. Around 53% of its territory is in the Amazon, 40% in the Cerrado and 7% in the Pantanal.

Due to this heterogeneity of land uses and vegetation types in the territory, the researchers applied the new methodology in Mato Grosso using data from the 2016–2017 strategic harvest, in which Brazil produced 115 million tons of soybeans, of which 30.7 million tons were in the state. Land use classifications were associated with agricultural land (fallow-cotton, soybean-cotton, soybean-corn, soybean-fallow, soybean-millet and soybean-sunflower), as well as sugarcane crops, urban areas and water bodies.

The results showed an overall accuracy of 95%, demonstrating the potential of the approach to provide mapping that optimizes forest and agricultural land delineation.

“Since the approach manages to identify the targets in a consistent manner, the methodology can be applied to the estimation of areas within the same harvest, favoring productivity estimates; in territorial planning actions and anything that deals with land use and land cover for decision-making,” explains Chaves about the application of the tool.

The professor explains that the methodology also makes it possible to analyze disturbances in forests and other types of natural vegetation: “It’s quicker to detect deforestation than degradation. This method allowed us to detect these variations more quickly.”

In the article, the scientists pay tribute to Professor Ieda Del’Arco Sanches, a remote sensing researcher at INPE who died in January.

“This article is a way of thanking her for her teachings and following her legacy. Ieda always worked to accurately assess Earth’s surface and to treat the data ethically and responsibly, showing how they can contribute to the construction of public policies,” adds Chaves.

A recent study on cell-cultivated fish has produced promising results that could put seafood back on the menu for the three to five percent of the global population with severe food allergies.

JCU researchers at the College of Science and Engineering, in collaboration with JCU’s Tropical Futures Institute in Singapore, have found that cell-based fish can lead to the production of safer seafood products with vastly diminished allergy risks, after analysis of cultivated Japanese eel (Unagi) showed positive signs.

Seafood is a leading trigger of food-induced anaphylaxis in many regions worldwide.

Research presented at the recent World Allergy Congress revealed that fish allergens in the cultivated Unagi were more than 10-fold lower compared to conventional eel.

Head of JCU’s Molecular Allergy Research Laboratory (MARL), Professor Andreas L. Lopata, said the study is showing hugely promising results. The research began almost a decade ago working with children who had a clinical history of allergies to bony fish.

“We have a data bank of over 100 children with confirmed fish allergies, and we demonstrated that there is very little to no reactivity to the known fish allergens in the cell-cultivated fish,” Prof Lopata said. “The levels of allergens present in the cell-cultivated fish being so low was quite surprising to us.

“You’re basically taking stem cells from the fish, growing them in tissue culture to the size they are edible, and everyone told us it would basically be the same as the regular fish including any allergy risks.

“Instead, we found diminished risks, including a decrease of up to 1000-fold of the predominant fish allergen parvalbumin, and all of this was with no manipulation nor gene modification.”

The JCU team is partnering with the not-for-profit organization Good Food Institute (GFI) and the Singapore-based company Umami Bioworks on the project and Prof Lopata expects the product could be available to consumers within the next few years.

“Cultivated chicken and quail products are already available in Singapore and the Food Standards Australia and New Zealand (FSANZ) is expected to approve the first cultivated meat products soon,” he said. “Worldwide you are looking at 10–12 billion US dollars in investments in the alternative protein production industry in recent years.

“The first products will most likely be cultivated fish and seafood dumplings. They should have that same fish flavor and omega-3 fatty acid levels, which are very healthy, along with all the other components of regular fish and seafood.”

The process of having these products approved by the Singapore Food Agency has already begun, with an obvious focus on Food Safety.

“There can be uncertainties about allergenicity, but that’s where we come in, as experts in the field, really analyzing all proteins (the proteome) and then comparing particular allergen patterns to see if there could be anything unsafe for consumers,” Prof Lopata said.